Compared to placebo, Xarelto reduces the risk of blood clots, like deep vein thrombosis (DVT), pulmonary embolism (PE) and stroke (cardiovascular accident). Although many in the health community say that Xarelto is a good option for prevention of deep vein thrombosis and pulmonary embolism and treating atrial fibrillation, there is a HUGE concern with this anticoagulant drug— the risk of life-threatening internal bleeding. In clinical trials, Xarelto resulted in more bleeding episodes compared to the placebo.
- Patients taking warfarin can have a bleeding episode reversed within half an hour, whereas there is no reversal agent to stop internal bleeding for patients on Xarelto. Although Bayer is currently working on an antidote to reverse the anti-clotting effects of Xarelto, this is too late for many patients who have suffered serious bleeds or died because there was no antidote to reverse the effects of Xarelto.
- Xarelto is out of a person’s system in about 24 hours, which means patients who miss a dose are at an increased risk of developing blood clots compared to patients missing a dose of warfarin.
- Patients taking warfarin have their blood monitored to check to see if they are at an increased risk for either bleeds or clots. Xarelto levels are not routinely checked and this creates the possibility that some patients are at an increased risk for bleeding and are completely unaware. This can lead to serious bleeds and death.